Inhibrx Biosciences Inc Dossier - Source-backed chat

Inhibrx Biosciences Inc

INBXNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)2.78

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $97.93Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $1.4B

Shares Outstanding 15.6M diluted

Next Earnings Date31 Oct 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Inhibrx Biosciences, Inc. represents a high-conviction, clinical-stage oncology play with two highly differentiated multivalent biologic candidates: ozekibart (INBRX-109) and INBRX-106. The company's proprietary protein engineering platform has successfully validated its therapeutic approach, culminating in the FDA's acceptance of the BLA for ozekibart in conventional chondrosarcoma with a PDUFA date of April 14, 2027. Furthermore, compelling interim Phase 2 data for INBRX-106 in first-line HNSCC (demonstrating a 44% ORR in combination with pembrolizumab vs. 21.4% for monotherapy) has triggered substantial strategic M&A interest from major pharmaceutical companies, including Merck & Co. While the company faces near-term cash runway constraints and a high debt load, the potential for a multi-billion dollar asset spin-off or licensing transaction provides a highly asymmetric risk-reward profile for investors.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$230.00

Mean target$277.50

High · most bullish analyst$325.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The FDA issues a Complete Response Letter (CRL) or delays approval for ozekibart in chondrosarcoma. INBRX-106 PFS data in Q4 2026 fails to show a statistically significant advantage over pembrolizumab monotherapy, dampening M&A interest. Unable to secure non-dilutive financing, the company is forced to execute highly dilutive equity offerings to service its $175 million debt.

Base CaseCentral scenario

Ozekibart receives FDA approval for conventional chondrosarcoma by the PDUFA date of April 14, 2027, establishing Inhibrx's first commercial product. INBRX-106 successfully transitions into Phase 3 development for HNSCC following positive PFS data in Q4 2026. The company secures a strategic partnership or non-dilutive licensing deal to extend its cash runway beyond 2027.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

FDA BLA acceptance for ozekibart in conventional chondrosarcoma with a clear PDUFA target of April 14, 2027.
Strong clinical validation for INBRX-106 in HNSCC, showing a near-doubling of ORR (44% vs 21.4%) when combined with pembrolizumab.
High strategic value and active M&A interest from global pharmaceutical companies seeking to mitigate Keytruda's 2028 patent cliff.
Proprietary modular protein engineering platform capable of optimizing precise valency for complex target biologies.

Key Investment Risks

Limited cash runway of approximately 12 months as of Q1 2026, requiring additional capital raises or strategic deals.
High leverage with $175 million in outstanding long-term debt carrying high interest rates.
Binary clinical and regulatory risks associated with late-stage oncology trials and FDA approval processes.
High historical accumulated deficit of $279.6 million reflecting pre-commercial development costs.

Thesis Invalidation Triggers

FDA rejection or major review extension of the ozekibart BLA for conventional chondrosarcoma.
Failure of INBRX-106 to demonstrate superior progression-free survival (PFS) in the Phase 2 HexAgon study in Q4 2026.
Inability to secure strategic partnerships, licensing deals, or non-dilutive financing before Q2 2027, leading to severe equity dilution.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.